Falber, Stuart M.

Stuart M. Falber

Falber, Stuart M.

Stuart M. Falber

Partner

  • Co-Chair, Life Sciences Group

Stuart Falber represents clients in the life sciences area. For more than 20 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association, as well as the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Experience

  • Venture Capital Transactions

    • Aileron Therapeutics, Inc. in its $48 million Series E financing rounds
    • Apellis Pharmaceuticals, Inc. in its $47 million Series D financing round
    • Celtaxsys, Inc. in its $40 million Series D financing round
    • Tokai Pharmaceuticals, Inc. in its 35.5 million Series E financing round
    • Trevi Therapeutics, Inc. in its $26 million Series B financing round
  • Public Offerings

    • Argos Therapeutics, Inc. in its $49.6 million initial public offering
    • Epizyme in multiple follow-on public offerings, including its $137.7 million public offering in January 2016
    • Idera Pharmaceuticals, Inc. in multiple follow-on public offerings, including its $86.25 million public offering in January 2015
    • The Medicines Company in a follow-on public offering raising a total of $201.2 million
    • Tetraphase Pharmaceuticals, Inc. in its $80.5 million initial public offering and in multiple follow-on public offerings, including its $173.1 million public offering in March 2015
    • Tokai Pharmaceuticals in its $105.3 million initial public offering
  • Merger and Acquisition Transactions

    • The Medicines Company in its acquisition of Incline Therapeutics for up to $390 million, including contingent payments
    • Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for $144 million
    • Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to $640 million, including contingent payments
    • Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for $16 billion
  • PIPE and 144A Transactions

    • The Medicines Company in 144A convertible note offerings, including its $350 million offering in January 2015
    • Argos Therapeutics, Inc. in its $60 million PIPE transaction
    • Idera Pharmaceuticals, Inc. in PIPE transactions raising a total of $17 million
    • New Leaf Ventures  in a PIPE transaction by MEI Pharma, Inc. raising a total of $27.5 million
  • Corporate Collaborations and Licensing Transactions

    • ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

Recognition

  • Named one of the 2017 and 2018 Best Lawyers in America in the areas of biotechnology law and corporate law
  • Recommended in the 2016 and 2017 editions of The Legal 500 United States for healthcare: life sciences and capital markets: equity offerings

Insights & News

Credentials

  • Education

    • JD, University of Pennsylvania Law School

      magna cum laude Order of the Coif; Senior Editor, University of Pennsylvania Law Review
    • BA, Tufts University

      cum laude
  • Admissions

    • Massachusetts

Credentials